A phase 1/2 study of the next-generation nectin-4–targeting antibody-drug conjugate CRB-701 (SYS6002) in patients with recurrent or metastatic cervical cancer.
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Tudor-Eliade Ciuleanu, Dominique Berton, Gennaro Daniele, Laurentia N. Gales, Diego Tosi, Giuseppe Curigliano, M. Julia Lostes-Bardaji, Lorenzo Antonuzzo, Bernard Gaston Doger de Spéville, Constantin D. Volovat, Debra Josephs, Guillermo Suay Montagud, David James Pinato, Sarah A. Ackroyd, Ivan Barrera, Kurt Preugschat, Paola M. Grant, Ian Hodgson, Dominic Smethurst, Yohann Loriot
Institutions: Institut de Cancérologie de l'Ouest, Agostino Gemelli University Polyclinic, Institut Regional du Cancer de Montpellier, University of Milan, European Institute of Oncology, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Azienda Ospedaliero-Universitaria Careggi, Institutul Oncologic din Republica Moldova, Guy's and St Thomas' NHS Foundation Trust, Hospital Universitari i Politècnic La Fe, Imperial College London, University of Chicago, Precision for Medicine (United States), Corbus Pharmaceuticals (United States), Université Paris-Saclay, Institut Gustave Roussy
Language: English
Subfield: Radiology, Nuclear Medicine and Imaging
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7162567024